Continuous theta burst stimulation to relieve symptoms in patients with moderate obsessive-compulsive disorder: a preliminary study with an external validation

• Published in: Translational psychiatry 2024-08, Vol.14 (1), p.321-6, Article 321
• Main Authors: Ni, Rui, Liu, Yueling, Jiang, Jin, Zhang, Wanying, Chen, Xuemeng, Liu, Jian, Tang, Wenxin, Wang, Kai, Zhu, Chunyan, Bu, Junjie
• Format: Article
• Language: English
• Subjects: 631/477/2811; 692/699/476; Achievement tests; Adult; Behavioral Sciences; Biological Psychology; Experiments; Female; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Motor Cortex - physiopathology; Neurosciences; Neuroses; Obsessive compulsive disorder; Obsessive-Compulsive Disorder - physiopathology; Obsessive-Compulsive Disorder - therapy; Pharmacotherapy; Psychiatry; Response rates; Theta Rhythm; Transcranial Magnetic Stimulation - methods; Treatment Outcome; Young Adult
• ISSN: 2158-3188; 2158-3188
• DOI: 10.1038/s41398-024-03041-4

Obsessive-compulsive disorder (OCD) is a clinically challenging and refractory psychiatric disorder characterized by pathologically hyperactivated brain activity. Continuous theta burst stimulation (cTBS) is considered a potentially non-invasive treatment for inducing inhibitory effects on the underlying cortex. Numerous studies showed an unsatisfactory efficacy of cTBS for OCD. Accordingly, it seems that cTBS is ineffective for OCD. However, the neglect of varying OCD severities, modest sample size, absence of a multicenter design incorporating inpatients and outpatients, and lack of personalized imaging-guided targeting may constrain the conclusive findings of cTBS efficacy for OCD. In the preliminary experiment, 50 inpatients with OCD were enrolled to receive cTBS (10 sessions/day for five continuous days) or sham over the personalized right pre-supplementary motor area determined by the highest functional connectivity with the subthalamic nucleus according to our prior study. In the extension experiment, 32 outpatients with OCD received cTBS to generalize the treatment effects. The Yale-Brown Obsessive-Compulsive Scale (YBOCS) was assessed before and after treatment. In the preliminary experiment, the response rates in the cTBS group were 56.52%, respectively, significantly higher than those in the sham group. Further analysis revealed significant YBOCS improvement in patients with moderate OCD symptoms than those with severe OCD symptoms. In the extension experiment, the response rates were 50.00%. Additionally, a significant decrease in YBOCS scores was only found in patients with moderate OCD symptoms. This is the first study with an external validation design across two centers to identify OCD symptoms as playing an important role in cTBS treatment effects, especially in patients with moderate OCD symptoms.